{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:49:18Z","timestamp":1769266158543,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajpc.2025.101058","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:33:35Z","timestamp":1753313615000},"page":"101058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Characteristics of patients prescribed SGLT-2i and\/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-2548","authenticated-orcid":false,"given":"Adam J","family":"Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Kaltenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein R.","family":"Al-Khalidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Leyva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A","family":"Cavender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L.","family":"Magwire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julienne K.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Pak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3509-9840","authenticated-orcid":false,"given":"Alana","family":"Washington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cagri","family":"Senyucel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha J","family":"Pagidipati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2025.101058_bib0001","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2025.101058_bib0002","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajpc.2025.101058_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101058_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajpc.2025.101058_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101058_bib0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101058_bib0007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ahj.2022.10.079","article-title":"Coordinating cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - diabetes: rationale and design","volume":"256","author":"Nelson","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajpc.2025.101058_bib0008","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ajpc.2025.101058_bib0009","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101058_bib0010","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2025.101058_bib0011","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA adverse event reporting system","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajpc.2025.101058_bib0012","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101058_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101419","article-title":"Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit\/risk balance?","volume":"49","author":"Scheen","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ajpc.2025.101058_bib0014","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/dom.13876","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men","volume":"22","author":"Radholm","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2025.101058_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108204","article-title":"Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes","volume":"36","author":"Limonte","year":"2022","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.ajpc.2025.101058_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis","volume":"174","author":"Karagiannis","year":"2021","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.ajpc.2025.101058_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108114","article-title":"Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials","volume":"162","author":"Giugliano","year":"2020","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.ajpc.2025.101058_bib0018","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpc.2025.101058_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009304","article-title":"Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: insights from the EXSCEL trial","volume":"7","author":"Mentz","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101058_bib0020","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/clinem\/dgab065","article-title":"Efficacy and safety of Dulaglutide in older patients: a post hoc analysis of the REWIND trial","volume":"106","author":"Riddle","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpc.2025.101058_bib0021","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2666-7568(23)00164-2","article-title":"Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study","volume":"4","author":"Malik","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.ajpc.2025.101058_bib0022","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2025.101058_bib0023","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12933-022-01713-3","article-title":"Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study","volume":"21","author":"Funck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2025.101058_bib0024","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2025.101058_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014742","article-title":"Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis","volume":"9","author":"Zhao","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101058_bib0026","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American college of cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:59:39Z","timestamp":1760648379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"alternative-id":["S2666667725001333"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101058","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of patients prescribed SGLT-2i and\/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101058"}}